.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Baxter
Daiichi Sankyo
Argus Health
Federal Trade Commission
Healthtrust
Teva
Cipla
Harvard Business School
Merck

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,089,567

« Back to Dashboard

Which drugs does patent 9,089,567 protect, and when does it expire?


Patent 9,089,567 protects ABILIFY MAINTENA KIT and ABILIFY and is included in three NDAs. There have been three Paragraph IV challenges on Abilify.

Summary for Patent: 9,089,567

Title:Method of treating cognitive impairments and schizophrenias
Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT.sub.1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) ##STR00001## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
Inventor(s): Jordan; Shaun (Germantown, MD), Kikuchi; Tetsuro (Tokushima, JP), Tottori; Katsura (Kamiita-cho, JP), Hirose; Tsuyoshi (Tokushima, JP), Uwahodo; Yasufumi (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., LTD. (Tokyo, JP)
Application Number:13/303,265
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Otsuka Pharm Co LtdABILIFY MAINTENA KITaripiprazoleFOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR202971-001Feb 28, 2013RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF SCHIZOPHRENIA
Otsuka Pharm Co LtdABILIFY MAINTENA KITaripiprazoleFOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR202971-003Sep 29, 2014RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF SCHIZOPHRENIA
Otsuka Pharm Co LtdABILIFY MAINTENA KITaripiprazoleFOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR202971-002Feb 28, 2013RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF SCHIZOPHRENIA
Otsuka Pharm Co LtdABILIFY MAINTENA KITaripiprazoleFOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR202971-004Sep 29, 2014RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF SCHIZOPHRENIA
OtsukaABILIFYaripiprazoleTABLET, ORALLY DISINTEGRATING;ORAL021729-002Jun 7, 2006DISCNNoNo► Subscribe► Subscribe► SubscribeTREATMENT OF SCHIZOPHRENIA
OtsukaABILIFYaripiprazoleTABLET, ORALLY DISINTEGRATING;ORAL021729-003Jun 7, 2006DISCNNoNo► Subscribe► Subscribe► SubscribeTREATMENT OF SCHIZOPHRENIA
OtsukaABILIFYaripiprazoleTABLET;ORAL021436-006Nov 15, 2002ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF SCHIZOPHRENIA
OtsukaABILIFYaripiprazoleTABLET;ORAL021436-005Nov 15, 2002ABRXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF SCHIZOPHRENIA
OtsukaABILIFYaripiprazoleTABLET;ORAL021436-001Nov 15, 2002ABRXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF SCHIZOPHRENIA
OtsukaABILIFYaripiprazoleTABLET;ORAL021436-002Nov 15, 2002ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF SCHIZOPHRENIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,089,567

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,680,105Method of treating down's syndrome► Subscribe
7,053,0925-HT1a receptor subtype agonist► Subscribe
8,722,680Method of treating neurodegenerative diseases► Subscribe
9,006,2485-HT.sub.1A receptor subtype agonist► Subscribe
8,642,600Method of treating autism► Subscribe
8,604,041Method of treating panic disorder► Subscribe
9,387,2075-HT1A receptor subtype agonist► Subscribe
8,623,874Method of treating neurodegenerative diseases► Subscribe
8,426,423Method of treating Attention Deficit Hyper-Activity Disorder► Subscribe
8,030,3125-HT1A receptor subtype agonist► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Queensland Health
Accenture
Moodys
Express Scripts
US Department of Justice
Chinese Patent Office
Harvard Business School
Dow
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot